Overview

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: This phase II trial is studying how well giving cyclophosphamide and fludarabine together with high-dose interleukin-2 works in treating patients with metastatic melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Aldesleukin
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Interleukin-2
Molgramostim
Sargramostim
Vidarabine